Pharma Sector

The Indian benchmark indices ended lower on June 11, 2026, with Nifty slipping to 23,161 and Sensex declining 150 points to close at 73,832, as a sharp selloff in IT stocks, fresh US-Iran escalation, and rising crude oil prices kept investor sentiment cautious through the session. Iran's declaration that the ceasefire had become "practically meaningless" rattled global markets, while weakness in AI-related stocks on Wall Street triggered broad selling in domestic technology counters. Nifty Bank managed a marginal gain of 76 points, with Media, Pharma, and Private Banks offering the only pockets of resilience in an otherwise weak session.

Indian benchmark indices ended on a mixed note on June 10, 2026, as geopolitical tensions, rising crude oil prices, rupee weakness, and persistent FII selling kept investors cautious. While FMCG and Private Bank stocks provided support, sectors such as Energy, Metals, Realty, and Media witnessed significant selling pressure ahead of key US inflation data.

The Indian stock market staged a strong recovery on June 9, 2026, as Nifty climbed 119 points and Sensex gained 394 points. Banking stocks surged following RBI's concessional FCNR(B) and ECB swap facilities, while lower crude oil prices, positive global market sentiment, progress in the India-US trade deal, and aviation sector tailwinds supported broad-based buying across Dalal Street.

SBI is considering a $1 billion commitment to help finance Sun Pharma’s proposed $12 billion acquisition of Organon. If approved, the deal would mark a major shift in Indian banks’ role in M&A financing following recent RBI regulatory reforms.

Hexagon Nutrition IPO attracted robust investor interest, with the issue subscribed 38.01 times on Day 3. The NII segment saw the highest demand, while retail investors subscribed 21.75 times. However, the GMP declined sharply from ₹12 to ₹3.5, suggesting a lower listing gain expectation despite strong subscription numbers.

Indian benchmark indices ended sharply lower on June 8, 2026, with Nifty closing at 23,123 and Sensex falling 719 points as geopolitical tensions between Iran and Israel, rising crude oil prices, weak global market sentiment, and US rate hike fears triggered a broad-based selloff across sectors.

Hexagon Nutrition IPO, a ₹138.87 crore book-built issue, opens for subscription from June 5 to June 9, 2026. The IPO is entirely an Offer for Sale (OFS), meaning the company will not receive any fresh capital. Backed by a diversified nutrition portfolio, export presence in over 75 countries, and improving profitability, the company offers exposure to India's growing nutrition and wellness sector. However, investors should consider customer concentration, dependence on the premix segment, and raw material price volatility before making an investment decision.

Bliss GVS Pharma touched a fresh 52-week high of ₹447 following WHO-GMP approval, strong FY26 financial performance, a 100% dividend declaration, and Anupam Rasayan's proposed acquisition of up to 74.2% stake in the company.

Indian benchmark indices ended in the red on June 3, 2026, dragged by a sharp sell-off in IT stocks after recent AI-driven gains. Rising crude oil prices, US-Iran tensions, FII outflows, and caution ahead of the RBI policy meeting weighed on sentiment. However, banking stocks outperformed, helping Bank Nifty close nearly 1% higher.

Indian benchmark indices rebounded on June 2, 2026, ending a four-session losing streak as a powerful rally in IT stocks lifted market sentiment. Nifty IT surged over 4%, supported by AI-driven growth expectations, positive global technology cues, and strong buying in large-cap tech stocks such as TCS, Infosys, and HCL Technologies. While consumer sectors also advanced, banking and financial stocks remained under pressure amid concerns over rising crude oil prices and inflation risks.